Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13012117 | 0.83 | HTT (0.59) | HTTSMN1; SMN2CTBP2ALDH1A1CYP3A4 | |
| SCHEMBL10608437 | 0.82 | CES1 (0.55) | CES1SMN1; SMN2ALDH1A1KDM4EPOLB | |
| SCHEMBL28376858 | 0.82 | HTT (0.54) | HTTSMN1; SMN2CTBP2ALDH1A1CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL7562496 | 0.82 | KDM4E (0.62) | HTTSMN1; SMN2CTBP2USP2TP53 | |
| SCHEMBL7634928 | 0.82 | F2RL1 (0.62) | SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6026975 | 0.81 | HTT (0.58) | HTTSMN1; SMN2CTBP2ALDH1A1CYP3A4 | |
| SCHEMBL28375576 | 0.81 | HTT (0.53) | HTTSMN1; SMN2CTBP2ALDH1A1CYP3A4 | |
| SCHEMBL5271327 | 0.80 | FAAH (0.60) | CES1ALDH1A1POLB | |
| SCHEMBL7562503 | 0.80 | KMT2A (0.52) | HTTSMN1; SMN2CTBP2ALDH1A1CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL5655817 | 0.80 | HTT (0.51) | HTTCTBP2ALDH1A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4519272-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-11873389-B2 | Composition and molded article | AKITA UNIVERSITY (JP) | 2024-01-16 | — | — | US | disclosed |
| WO-2023215449-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-20 | — | — | US | disclosed |
| CN-108976170-B | 5-trifluoromethyl-4H-imidazoline-4-ketone derivative and synthetic method thereof | 华南理工大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-109232310-B | Trifluoroacetyl group substituted hydrazone derivative and synthesis method thereof | 华南理工大学 | 2021-08-10 | — | — | CN | disclosed |
| CN-109232310-A | A kind of trifluoroacetyl group replaces hydazone derivative and its synthetic method | 华南理工大学 | 2019-01-18 | — | — | CN | disclosed |
| CN-108976170-A | A kind of 5- trifluoromethyl -4H- imidazoline -4- ketone derivatives and synthetic method | 华南理工大学 | 2018-12-11 | — | — | CN | disclosed |
| EP-2660255-B1 | Block copolymers for stable micelles | INTEZYNE TECHNOLOGIES INC (US) | 2015-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | HCRTR1, HCRTR2, CRHR1 | CES1 1845/4885HTT 111/4885SMN1; SMN2 3005/4885 |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2L1, BCL2, BCL2L10 | CES1 3681/4885HTT 350/4885SMN1; SMN2 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.